Work

Costs and Access Barriers to Ondansetron in the US

Year: 2024

Type: article

Abstract: This cross-sectional study compares the use of management tools and plan-level total costs for oral ondansetron between Part D independent prescription drug plans and Medicare Advantage prescription drug plans.

Source: JAMA Network Open

DOI: 10.1001/jamanetworkopen.2024.43978

Authors: Changchuan Jiang, K. Robin Yabroff, Ryan D. Nipp, Xuesong Han, Xin Hu, Joshua M. Liao, Ya-Chen Tina Shih

Institutions: The University of Texas Southwestern Medical Center, American Cancer Society, University of Oklahoma Health Sciences Center, Emory University, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

OpenAlex ID: W4404137044

FWCI: 1.067

Cites: 4

Cited by: 3

Related to: 10